2026-11-20 · Artemisine Editorial Team
The World Health Organization (WHO) issued its first-ever guidelines on the diagnosis and management of type 1 diabetes in adults on 14 November 2026, marking World Diabetes Day 2026. The recommendations are designed to apply across all settings, including low-resource, emergency and humanitarian settings, where health services are frequently disrupted.
Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, leaving people dependent on daily insulin to survive. WHO notes that more than 100 years after insulin's discovery, many people still cannot access the insulin and care they need. In 2025, around 9.5 million people lived with type 1 diabetes globally, with an additional 500,000 diagnosed that year. Long regarded as primarily a childhood condition, it is increasingly affecting adults.
The guidelines recommend insulin injections several times per day, with doses adjusted to blood glucose levels. WHO states that human insulin, a manufactured medicine that works like the body's own insulin, is an appropriate and effective option, while other insulin types can be used when needed. Regular blood glucose monitoring is also advised: at clinics through a blood test showing average sugar levels over recent months, and at home through a finger-prick test or a continuous glucose monitor worn as a small skin sensor. Where blood glucose testing is unavailable, urine glucose testing can be considered.
The recommendations support WHO targets to ensure all people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring by 2030. WHO will help countries translate the recommendations into action with practical tools and progress-tracking guidance, and encourages governments to involve people living with the condition in designing and evaluating diabetes programmes. The 2026 World Diabetes Day theme, "Early action on diabetes", reflects a wider burden: the global number of people with diabetes has more than quadrupled since 1990, reaching 830 million in 2022, mostly type 2, with more than 40 percent undiagnosed. Unmanaged diabetes can cause blindness, kidney failure, heart attack, stroke and lower-limb amputation.
For procurement teams, distributors and programme partners, the first adult type 1 diabetes guidance is a clear demand signal. Recommendations that apply explicitly in low-resource and humanitarian settings reinforce the need for quality-assured human insulin with reliable cold-chain handling, alongside self-monitoring tools from test strips to continuous glucose monitors. Human insulin being named an appropriate and effective option is particularly relevant for public tenders and essential-medicines lists, where affordability and assured quality carry most weight. Suppliers able to document consistent GMP manufacturing, stable supply and complete registration dossiers are well placed to support national programmes working toward the 2030 access targets.
Source: WHO, WHO issues first guidelines on type 1 diabetes for adults, https://www.who.int/news/item/14-11-2026-who-issues-first-guidelines-on-type-1-diabetes-for-adults